- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Sotagliflozin Impact on Stroke, MI to Be Explored in 4 Posters at ACC.24
The novel SGLT-2/SGLT-1 inhibitor reduced risk of stroke, MI, and demonstrates significant antiplatelet activity in post-hoc analyses of SCORED phase 3 trial.
The impact of sotagliflozin (Inpefa) on the risk of stroke and myocardial infarction (MI) will be explored during 4 poster presentations at the American College of Cardiology 73rd Scientific Sessions (ACC.24), being held in Atlanta, GA, from March 26 to 28, 2024, according to an announcement from Lexicon Pharmaceuticals.
Sotagliflozin, a novel inhibitor of 2 sodium glucose transport proteins (SGLT2 and SGLT1), was approved by the US Food and Drug Administration (FDA) in May 2023 with an indication for treatment of adults with the full range of heart failure, including both reduced and preserved ejection fraction, and with or without type 2 diabetes (T2D).
Data presented during the ACC.24 Scientific Sessions will include results from post-hoc analyses of the SCORED phase 3 clinical trial on the efficacy of sotagliflozin to reduce stroke in study participants with T2D, chronic kidney disease (CKD), and at high cardiovascular (CV) risk and on characteristics of the molecule that highlight its platelet inhibition properties.
